



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/806,302	07/19/2001	Roberto A Macina	DEX-0180	6964
26259	7590	12/02/2004	EXAMINER	
LICATLA & TYRRELL P.C. 66 E. MAIN STREET MARLTON, NJ 08053			HOLLERAN, ANNE L	
			ART UNIT	PAPER NUMBER
			1642	

DATE MAILED: 12/02/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Office Action Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	09/806,302	MACINA, ROBERTO A	
	<b>Examiner</b>	<b>Art Unit</b>	
	Anne Holleran	1642	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

#### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

- 1) ☒ Responsive to communication(s) filed on 07 September 2004.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

- 4) ☒ Claim(s) 1 and 11-20 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1,11,12,15,18 and 21 is/are rejected.
- 7) ☒ Claim(s) 13,14,16,17,19 and 20 is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☒ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)  
Paper No(s)/Mail Date \_\_\_\_\_.

- 4) ☐ Interview Summary (PTO-413)  
Paper No(s)/Mail Date. \_\_\_\_\_.

- 5) ☐ Notice of Informal Patent Application (PTO-152)

- 6) ☒ Other: Sequence alignments, 5, 6, 7 <sup>pages</sup>

## **DETAILED ACTION**

### ***Continued Examination Under 37 CFR 1.114***

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 9/7/2004 has been entered.

Claims 2-10 are canceled and claims 11-21 are added. Claims 1 and 11-21 are pending and examined on the merits.

2. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

### ***Claim Rejections Withdrawn:***

3. The rejection of claims 1, 3, and 5 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention is withdrawn in view of the amendment.

4. The rejection of claims 2 and 4 under 35 U.S.C. 102(e) as being anticipated by Lehrer (Lehrer et al, U.S. Pub. NO.: US 2002/0034739, published March 21, 2002, filing date July 7, 1998) is withdrawn in view of the amendment.

Art Unit: 1642

***New Grounds of Rejection:***

5. Claims 1, 11, 12, 15, 18, and 21 are rejected under 35 U.S.C. 103(a) as being unpatentable over Lehrer (Lehrer et al, U.S. Pub. NO.: US 2002/0034739 in view of either Ni (U.S. Patent 6,066724; issued May 23, 2000; effective filing date Mar. 21, 1996; cited in the IDS) or Gentz (WO 97/34997; published 25 Sep. 1997; cited in the IDS).

The claimed inventions are drawn to methods for detecting the presence of uterine or ovarian cancer in a patient, comprising measuring levels of a polynucleotide comprising SEQ ID NO: 1 (a polynucleotide encoding ESBPIII having the sequence SEQ ID NO: 2); and comparing the measured levels of the polynucleotide with levels of the polynucleotide in cells, tissues or bodily fluids from a normal human control, wherein an increase in measured levels of the polynucleotide in the patient versus the normal human control is associated with the presence of uterine or ovarian cancer. Because the claims are drawn to methods where the measurements are made in bodily fluids the claimed methods read on detection of metastasis of uterine or ovarian cancer.

Lehrer teaches methods of detection of metastasis of uterine or ovarian cancer comprising the detection of polynucleotides encoding ESBPIII in bodily fluids such as blood. Lehrer fails to teach the specific polynucleotide sequence of SEQ ID NO: 1, but the polynucleotide of Lehrer encodes the same polypeptide as that encoded by SEQ ID NO: 1. Lehrer contemplates detection of genomic variants of polynucleotides encoding the polypeptide encoded by SEQ ID NO: 1. Ni or Gentz teaches a polynucleotide that encodes the polypeptide encoded by SEQ ID NO: 1 and teaches the specific polynucleotide comprising SEQ ID NO: 1 (see enclosed sequence alignments). Therefore, it would have been prima facie obvious to one of ordinary skill in the art

Art Unit: 1642

at the time the invention was made to make a method for the detection of the polynucleotide of Ni or Gentz in the methods of Lehrer to detect uterine or ovarian cancer metastasis in a bodily fluid, because Lehrer teaches methods for detection of metastasis of uterine or ovarian cancer by measurement of the presence of polynucleotides encoding ESBPIII, and because the sequence of SEQ ID NO: 1 was provided by Ni or Gentz prior to the filing date of this application.

***Conclusion***


Claims 1, 11, 12, 15, 18, and 21 are rejected. Claims 13, 14, 16, 17, 19 and 20 are objected to depending from a rejected claim.

Any inquiry concerning this communication or earlier communications from the Office should be directed to Anne Holleran, Ph.D. whose telephone number is (571) 272-0833. Examiner Holleran can normally be reached Monday through Friday, 9:30 am to 3:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jeffrey Siew, can be reached at (571) 272-0787.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist at telephone number (703) 571-1600.

Anne L. Holleran  
Patent Examiner  
November 27, 2004

  
**ALANA M. HARRIS, PH.D.**  
**PRIMARY EXAMINER**  
11/29/2004

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: November 12, 2004, 22:05:44 ; Search time 58 Seconds  
(without alignments)  
5833.371 Million cell updates/sec

Title: US-09-806-302A-1  
Perfect score: 476  
Sequence: 1 acgagctgccacgcagcatttca 476

Scoring table: IDENTITY NUC  
Gapop 10.0 , Gapext 1.0

Searched: 824507 seqs, 355394441 residues

Total number of hits satisfying chosen parameters: 1649014

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : Issued Patents NA.\*  
1: /cgn2\_6/ptodata/1/ina/5A\_COMB.seq.\*  
2: /cgn2\_6/ptodata/1/ina/5B\_COMB.seq.\*  
3: /cgn2\_6/ptodata/1/ina/6A\_COMB.seq.\*  
4: /cgn2\_6/ptodata/1/ina/6B\_COMB.seq.\*  
5: /cgn2\_6/ptodata/1/ina/PCTUS\_COMB.seq.\*  
6: /cgn2\_6/ptodata/1/ina/backfiles1.seq.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	ID	Description
1	476	100.0	476	US-08-821-451A-5	Sequence 5, Appli
2	476	100.0	476	US-09-263-810-5	Sequence 5, Appli
3	476	100.0	476	US-09-583-169-5	Sequence 5, Appli
4	431.6	90.7	517	US-09-673-395A-33	Sequence 33, Appli
5	223.8	47.0	495	US-08-969-987-5	Sequence 5, Appli
6	223.8	47.0	503	US-08-455-896-1	Sequence 1, Appli
7	223.8	47.0	503	US-08-933-149-1	Sequence 1, Appli
8	223.8	47.0	503	US-09-082-343-1	Sequence 1, Appli
9	223.8	47.0	503	US-09-082-253-1	Sequence 1, Appli
10	223.8	47.0	503	US-09-162-622-1	Sequence 1, Appli
11	223.8	47.0	503	US-09-509-015-1	Sequence 1, Appli
12	223.8	47.0	503	PCT-US96-08235-1	Sequence 1, Appli
13	223.8	47.0	535	US-09-215-818-1	Sequence 1, Appli
14	223.8	47.0	535	US-09-467-602A-1	Sequence 1, Appli
15	201.2	42.3	403	US-08-455-896-5	Sequence 5, Appli
16	201.2	42.3	403	US-08-933-149-5	Sequence 5, Appli
17	201.2	42.3	403	US-09-082-343-5	Sequence 5, Appli
18	201.2	42.3	403	US-09-082-253-5	Sequence 5, Appli
19	201.2	42.3	403	US-09-162-622-5	Sequence 5, Appli
20	201.2	42.3	403	US-09-509-015-5	Sequence 5, Appli
21	201.2	42.3	403	PCT-US96-08235-5	Sequence 5, Appli
22	153.4	32.2	279	US-09-162-622-15	Sequence 15, Appli
23	153.4	32.2	1233	US-09-620-405B-492	Sequence 492, App
24	153.4	32.2	1233	US-09-834-759-492	Sequence 492, App
25	153.4	32.2	2232	US-09-620-405B-491	Sequence 491, App
26	153.4	32.2	2232	US-09-834-759-491	Sequence 491, App
27	153.4	32.2	3288	US-09-620-405B-490	Sequence 490, App

28	153.4	32.2	3288	4	US-09-834-759-490	Sequence 490, App
29	140.2	29.5	356	4	US-09-389-681-217	Sequence 217, App
30	140.2	29.5	356	4	US-09-620-405B-217	Sequence 217, App
31	140.2	29.5	356	4	US-09-339-338-217	Sequence 217, App
32	140.2	29.5	356	4	US-09-433-826B-217	Sequence 217, App
33	140.2	29.5	356	4	US-09-604-287A-217	Sequence 217, App
34	140.2	29.5	356	4	US-09-834-759-217	Sequence 217, App
35	140.2	29.5	356	4	US-09-590-751A-217	Sequence 217, App
36	122.4	25.7	511	4	US-09-389-681-182	Sequence 182, App
37	122.4	25.7	511	4	US-09-620-405B-182	Sequence 182, App
38	122.4	25.7	511	4	US-09-339-338-182	Sequence 182, App
39	122.4	25.7	511	4	US-09-433-826B-182	Sequence 182, App
40	122.4	25.7	511	4	US-09-604-287A-182	Sequence 182, App
41	122.4	25.7	511	4	US-09-834-759-182	Sequence 182, App
42	122.4	25.7	511	4	US-09-590-751A-182	Sequence 182, App
43	57.2	12.0	206	1	US-08-455-896-6	Sequence 6, Appli
44	57.2	12.0	206	2	US-08-933-149-6	Sequence 6, Appli
45	57.2	12.0	206	2	US-09-082-343-6	Sequence 6, Appli

ALIGNMENTS

RESULT 1  
US-08-821-451A-5  
; Sequence 5, Application US/08821451A  
; Patent No. 6066724  
; GENERAL INFORMATION:  
; APPLICANT: Jian Ni, Guo-Liang Yu and Reiner Gentz  
; TITLE OF INVENTION: Human Endometrial Specific Steroid-  
; BINDING FACTOR I, II and III  
; NUMBER OF SEQUENCES: 27  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: CARELIA, BYRNE, BAIN, GILFILLAN,  
; ADDRESSEE: CECCHI, STEWART & OLSTEIN  
; STREET: 6 BECKER FARM ROAD  
; CITY: ROSELAND  
; STATE: NEW JERSEY  
; COUNTRY: USA  
; ZIP: 07068  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: 3.5 INCH DISKETTE  
; COMPUTER: IBM PS/2  
; OPERATING SYSTEM: MS-DOS  
; SOFTWARE: WORD PERFECT 5.1  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/821,451A  
; FILING DATE: March 21, 1997  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 60/014,724  
; FILING DATE: March 21, 1996  
; ATTORNEY/AGENT INFORMATION:  
; NAME: MULLINS, J.G.  
; REGISTRATION NUMBER: 33,073  
; REFERENCE/DOCKET NUMBER: 325800-521 (PF257)  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 201-994-1700  
; TELEFAX: 201-994-1744  
; INFORMATION FOR SEQ ID NO: 5:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 476 BASE PAIRS  
; TYPE: NUCLEIC ACID  
; STRANDEDNESS: SINGLE  
; TOPOLOGY: LINEAR  
; MOLECULE TYPE: cDNA  
US-08-821-451A-5

Query Match 100.0%; Score 476; DB 3; Length 476;  
Best Local Similarity 100.0%; Pred. No. 4.6e-145;  
Matches 476; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGAGCTGCCACGACGACTGAACACAGACAGCCGCTGCCATGAGCTGCTGATG 60

Db 1 ACGAGCTGCCACGACGACTGAACACAGACAGCCGCTCGCCATGAAGCTGCTGATG 60  
QY 61 GTCCTCATGCTGGGGCCCTCTCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 120  
Db 61 GTCCTCATGCTGGGGCCCTCTCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 120  
QY 121 GAGGACATGTTGAAAGAGACCATCAATTCGACATATCTATACCTGAATCAAGAGCTT 180  
Db 121 GAGGACATGTTGAAAGAGACCATCAATTCGACATATCTATACCTGAATCAAGAGCTT 180  
QY 181 CTTCAAGAGTTTCATAGACAGTGCCTGCTGAGAGGCTATGGGAAATTCAGCAGTGT 240  
Db 181 CTTCAAGAGTTTCATAGACAGTGCCTGCTGAGAGGCTATGGGAAATTCAGCAGTGT 240  
QY 241 TTCCTCAACAGTGCATAGACAGTGCCTGCTGAGAGGCTATGGGAAATTCAGCAGTGT 300  
Db 241 TTCCTCAACAGTGCATAGACAGTGCCTGCTGAGAGGCTATGGGAAATTCAGCAGTGT 300  
QY 301 GACAGCATTTGGTGAATATGAAGAGTAATTAACCTTACCCAGGCGTTGGCTCAGAGG 360  
Db 301 GACAGCATTTGGTGAATATGAAGAGTAATTAACCTTACCCAGGCGTTGGCTCAGAGG 360  
QY 361 GCTACAGACTATGGCCAGAACTCATCTGTTGATTGCTAGAAACCACTTTCTTGTGTT 420  
Db 361 GCTACAGACTATGGCCAGAACTCATCTGTTGATTGCTAGAAACCACTTTCTTGTGTT 420  
QY 421 GCTTTTATGTTGGGAACTGCTAGACAACTGTTGAAACCTCAATTCATTCCATTCA 476  
Db 421 GCTTTTATGTTGGGAACTGCTAGACAACTGTTGAAACCTCAATTCATTCCATTCA 476

RESULT 2  
US-09-263-810-5  
; Sequence 5, Application US/09263810  
; Patent No. 6174992  
; GENERAL INFORMATION:  
; APPLICANT: Jian Ni, Guo-Liang Yu and Reiner Gentz  
; TITLE OF INVENTION: Human Endometrial Specific Steroid-  
; TITLE OF INVENTION: Binding Factor I, II and III  
; NUMBER OF SEQUENCES: 27  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: CARELLA, BYRNE, BAIN, GILFILLAN,  
; STREET: 6 BECKER FARM ROAD  
; CITY: ROSELAND  
; STATE: NEW JERSEY  
; COUNTRY: USA  
; ZIP: 07068  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: 3.5 INCH DISKETTE  
; COMPUTER: IBM PS/2  
; OPERATING SYSTEM: MS-DOS  
; SOFTWARE: WORD PERFECT 5.1  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/263,810  
; FILING DATE:  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/821,451  
; FILING DATE:  
; ATTORNEY/AGENT INFORMATION:  
; NAME: MULLINS, J.G.  
; REGISTRATION NUMBER: 33,073  
; REFERENCE/DOCKET NUMBER: 325800-521 (PF257)  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 201-994-1700  
; TELEFAX: 201-994-1744  
; INFORMATION FOR SEQ ID NO: 5:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 476 BASE PAIRS  
; TYPE: NUCLEIC ACID  
; STRANDEDNESS: SINGLE

TOPOLOGY: LINEAR  
MOLECULE TYPE: CDNA  
US-09-263-810-5  
Query Match 100.0%; Score 476; DB 3; Length 476;  
Best Local Similarity 100.0%; Pred. No. 4.6e-145;  
Matches 476; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 ACGAGTGCACGACGACTGAACACAGACAGCCGCTCGCCATGAAGCTGCTGATG 60  
Db 1 ACGAGTGCACGACGACTGAACACAGACAGCCGCTCGCCATGAAGCTGCTGATG 60  
QY 61 GTCCTCATGCTGGGGCCCTCTCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 120  
Db 61 GTCCTCATGCTGGGGCCCTCTCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 120  
QY 121 GAGGACATGTTGAAAGAGACCATCAATTCGACATATCTATACCTGAATCAAGAGCTT 180  
Db 121 GAGGACATGTTGAAAGAGACCATCAATTCGACATATCTATACCTGAATCAAGAGCTT 180  
QY 181 CTTCAAGAGTTTCATAGACAGTGCCTGCTGAGAGGCTATGGGAAATTCAGCAGTGT 240  
Db 181 CTTCAAGAGTTTCATAGACAGTGCCTGCTGAGAGGCTATGGGAAATTCAGCAGTGT 240  
QY 241 TTCCTCAACAGTGCATAGACAGTGCCTGCTGAGAGGCTATGGGAAATTCAGCAGTGT 300  
Db 241 TTCCTCAACAGTGCATAGACAGTGCCTGCTGAGAGGCTATGGGAAATTCAGCAGTGT 300  
QY 301 GACAGCATTTGGTGAATATGAAGAGTAATTAACCTTACCCAGGCGTTGGCTCAGAGG 360  
Db 301 GACAGCATTTGGTGAATATGAAGAGTAATTAACCTTACCCAGGCGTTGGCTCAGAGG 360  
QY 361 GCTACAGACTATGGCCAGAACTCATCTGTTGATTGCTAGAAACCACTTTCTTGTGTT 420  
Db 361 GCTACAGACTATGGCCAGAACTCATCTGTTGATTGCTAGAAACCACTTTCTTGTGTT 420  
QY 421 GCTTTTATGTTGGGAACTGCTAGACAACTGTTGAAACCTCAATTCATTCCATTCA 476  
Db 421 GCTTTTATGTTGGGAACTGCTAGACAACTGTTGAAACCTCAATTCATTCCATTCA 476

RESULT 3  
US-09-583-169-5  
; Sequence 5, Application US/09583169  
; Patent No. 6338948  
; GENERAL INFORMATION:  
; APPLICANT: Jian Ni, Guo-Liang Yu and Reiner Gentz  
; TITLE OF INVENTION: Human Endometrial Specific Steroid-  
; TITLE OF INVENTION: Binding Factor I, II and III  
; NUMBER OF SEQUENCES: 27  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: CARELLA, BYRNE, BAIN, GILFILLAN,  
; ADDRESSEE: CECCHI, STEWART & OLSTEIN  
; STREET: 6 BECKER FARM ROAD  
; CITY: ROSELAND  
; STATE: NEW JERSEY  
; COUNTRY: USA  
; ZIP: 07068  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: 3.5 INCH DISKETTE  
; COMPUTER: IBM PS/2  
; OPERATING SYSTEM: MS-DOS  
; SOFTWARE: WORD PERFECT 5.1  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/583,169  
; FILING DATE:  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/821,451  
; FILING DATE:  
; ATTORNEY/AGENT INFORMATION:  
; NAME: MULLINS, J.G.  
; REGISTRATION NUMBER: 33,073

APPLICANT: Gentz, Reiner  
TITLE OF INVENTION: HUMAN ENDOMETRIAL SPECIFIC  
TITLE OF INVENTION: STEROID-BINDING FACTOR I, II AND III  
NUMBER OF SEQUENCES: 27  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: CARELLA, BYRNE, BAIN, GILFILLAN, CECCHI,  
ADDRESSEE: STEWART & OLSTEIN  
STREET: 6 BECKER FARM ROAD  
CITY: ROSELAND  
STATE: NEW JERSEY  
COUNTRY: USA  
ZIP: 07068-1739  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent in Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: PCT/US96/03857  
FILING DATE:  
CLASSIFICATION:  
ATTORNEY/AGENT INFORMATION:  
NAME: Ferraro, Gregory D  
REGISTRATION NUMBER: 36,134  
REFERENCE/DOCKET NUMBER: 325800-520  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 201-994-1700  
TELEFAX: 201-994-1744  
INFORMATION FOR SEQ ID NO: 5:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 476 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA (genomic)  
FEATURE:  
NAME/KEY: CDS  
LOCATION: 46...330  
FEATURE:  
NAME/KEY: sig\_peptide  
LOCATION: 46...108  
FEATURE:  
NAME/KEY: mat\_peptide  
LOCATION: 109...330  
PCT-US96-03857-5

Query Match 100.0%; Score 476; DB 1; Length 476;  
Best Local Similarity 100.0%; Pred. No. 1.9e-130;  
Matches 476; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 ACGAGCTGCCACGACGACTGAACACACAGACAGCAGCGCGCTCGCCATGAAGCTGCTGATG 60  
Db 1 ACGAGCTGCCACGACGACTGAACACACAGACAGCAGCGCGCTCGCCATGAAGCTGCTGATG 60  
QY 61 GTCCTCATGTGGCGGCGCTCCTCTGCACTGCTATGAGATTCTGCTGCAAACTCCTG 120  
Db 61 GTCCTCATGTGGCGGCGCTCCTCTGCACTGCTATGAGATTCTGCTGCAAACTCCTG 120  
QY 121 GAGGACATGTTGAAAGACCATCAATCCGACATATCTATACCTGAATACAAAGAGCTT 180  
Db 121 GAGGACATGTTGAAAGACCATCAATCCGACATATCTATACCTGAATACAAAGAGCTT 180  
QY 181 CTTCAAGAGTTTCATAGACAGTATGCCGCTGCAGAGGCTATGGGAAATTCAGCAGTGT 240  
Db 181 CTTCAAGAGTTTCATAGACAGTATGCCGCTGCAGAGGCTATGGGAAATTCAGCAGTGT 240  
QY 241 TTCCTCAACAGTTCATAGACAGTATGCCGCTGCAGAGGCTATGGGAAATTCAGCAGTGT 300  
Db 241 TTCCTCAACAGTTCATAGACAGTATGCCGCTGCAGAGGCTATGGGAAATTCAGCAGTGT 300  
QY 301 GACAGCATTGTTGTTAATATGAGAGTAATTAACCTTTACCAAGGCGTTTGGCTCAGAGG 360  
Db 301 GACAGCATTGTTGTTAATATGAGAGTAATTAACCTTTACCAAGGCGTTTGGCTCAGAGG 360

Mon Nov 15 09:13:30 2004

us-09-806

QY 361 GCTACAGACTATGGCCAGAACTCATCTGTTGATTTGCTAGAAACCACTTTCTTCTTGTGTT 420  
Db 361 GCTACAGACTATGGCCAGAACTCATCTGTTGATTTGCTAGAAACCACTTTCTTCTTGTGTT 420  
QY 421 GCTTTTATGTTGGGAACTGCTAGACAACTGTTGAAACCTCAATTCATTCCATTCA 476  
Db 421 GCTTTTATGTTGGGAACTGCTAGACAACTGTTGAAACCTCAATTCATTCCATTCA 476

## RESULT 2

PCT-US99-22753-1  
; Sequence 1, Application PC/TUS9922753  
; GENERAL INFORMATION:  
; APPLICANT: Macina, Roberto A.  
; APPLICANT: DIADEXUS LLC  
; TITLE OF INVENTION: A Novel Method of Diagnosing, Monitoring, Staging,  
; TITLE OF INVENTION: Imaging and Treating Gynecologic Cancers  
; FILE REFERENCE: DEX-0045  
; CURRENT APPLICATION NUMBER: PCT/US99/22753  
; CURRENT FILING DATE: 1999-09-30  
; EARLIER APPLICATION NUMBER: 60/102,743  
; EARLIER FILING DATE: 1998-10-02  
; NUMBER OF SEQ ID NOS: 2  
; SOFTWARE: Patent in Ver. 2.0  
; SEQ ID NO 1  
; LENGTH: 476  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
PCT-US99-22753-1

Query Match 100.0%; Score 476; DB 1; Length 476;  
Best Local Similarity 100.0%; Pred. No. 1.9e-130;  
Matches 476; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGAGCTGCCACGACGACTGAACACACAGACAGCAGCGCGCTCGCCATGAAGCTGCTGATG 60  
Db 1 ACGAGCTGCCACGACGACTGAACACACAGACAGCAGCGCGCTCGCCATGAAGCTGCTGATG 60  
QY 61 GTCCTCATGTGGCGGCGCTCCTCTGCACTGCTATGAGATTCTGCTGCAAACTCCTG 120  
Db 61 GTCCTCATGTGGCGGCGCTCCTCTGCACTGCTATGAGATTCTGCTGCAAACTCCTG 120  
QY 121 GAGGACATGTTGAAAGACCATCAATCCGACATATCTATACCTGAATACAAAGAGCTT 180  
Db 121 GAGGACATGTTGAAAGACCATCAATCCGACATATCTATACCTGAATACAAAGAGCTT 180  
QY 181 CTTCAAGAGTTTCATAGACAGTATGCCGCTGCAGAGGCTATGGGAAATTCAGCAGTGT 240  
Db 181 CTTCAAGAGTTTCATAGACAGTATGCCGCTGCAGAGGCTATGGGAAATTCAGCAGTGT 240  
QY 241 TTCCTCAACAGTTCATAGACAGTATGCCGCTGCAGAGGCTATGGGAAATTCAGCAGTGT 300  
Db 241 TTCCTCAACAGTTCATAGACAGTATGCCGCTGCAGAGGCTATGGGAAATTCAGCAGTGT 300  
QY 301 GACAGCATTGTTGTTAATATGAGAGTAATTAACCTTTACCAAGGCGTTTGGCTCAGAGG 360  
Db 301 GACAGCATTGTTGTTAATATGAGAGTAATTAACCTTTACCAAGGCGTTTGGCTCAGAGG 360  
QY 361 GCTACAGACTATGGCCAGAACTCATCTGTTGATTTGCTAGAAACCACTTTCTTCTTGTGTT 420  
Db 361 GCTACAGACTATGGCCAGAACTCATCTGTTGATTTGCTAGAAACCACTTTCTTCTTGTGTT 420  
QY 421 GCTTTTATGTTGGGAACTGCTAGACAACTGTTGAAACCTCAATTCATTCCATTCA 476  
Db 421 GCTTTTATGTTGGGAACTGCTAGACAACTGTTGAAACCTCAATTCATTCCATTCA 476